RxDoctor Payments Data

Tamra Ward, APRN

Nurse Practitioner · Hollywood, FLNPI 1689780199

Payments from drug & device makers

$2,347in general payments, 2019–2025

Across 30 payments — averaging $78.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$488
  • E.r. Squibb & Sons, L.L.C.$315
  • Gilead$266
  • Actelion Pharmaceuticals US, Inc.$169
  • Pulmonx Corporation$168
  • Alnylam Pharmaceuticals Inc.$160
  • plus $781 from 10 others

What the payments were for

  • Food & beverage$2,11090%
  • Education$23710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,347 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$14,450
Medicare patients
94
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis47$994,747
UptraviSelexipag28$596,858
OpsumitMacitentan34$421,548
AdempasRiociguat13$177,903
EntrestoSacubitril/Valsartan159$154,600
FarxigaDapagliflozin Propanediol96$70,345
EliquisApixaban50$40,771
JardianceEmpagliflozin51$36,316
OzempicSemaglutide12$9,878
XareltoRivaroxaban12$8,897
Milrinone Lactate26$7,729
Eplerenone16$1,165
Spironolactone132$1,139
Bumetanide30$1,039
Metoprolol Succinate75$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$46$1,035,51897 claims
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$169$1,018,40662 claims
BayerAdempas$68$177,90313 claims
AstraZenecaFarxiga$488$70,34596 claims
Boehringer IngelheimJardiance$47$36,31651 claims
Novo NordiskOzempic$125$9,87812 claims
Johnson & JohnsonXarelto$125$8,89712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →